Latest Articles

Publication Date
MSU researchers make progress toward non-hormonal treatment for endometriosis - MSUToday

MSU researchers make progress toward non-hormonal treatment for endometriosis MSUToday

Published: March 21, 2025, 2 p.m.
A Fibronectin (FN)-Silk 3D Cell Culture Model as a Screening Tool for Repurposed Antifibrotic Drug Candidates for Endometriosis.

This study advances sustainable pharmaceutical research for endometriosis by developing in vitro 3D cell culture models of endometriotic pathophysiology that allow antifibrotic drug candidates to be tested. Fibrosis is a …

Published: Feb. 19, 2025, midnight
Reprogramming peritoneal macrophages with outer membrane vesicle-coated PLGA nanoparticles for endometriosis prevention.

Endometriosis is a chronic inflammatory disease that primarily affects women of reproductive age. The current hormonal treatments are unsuitable for women who wish to conceive, highlighting the need for non-hormonal …

Published: Feb. 17, 2025, midnight
Gesynta Pharma Raises $29M to Advance Non-Hormonal Endometriosis Treatment - Femtech Insider

Gesynta Pharma Raises $29M to Advance Non-Hormonal Endometriosis Treatment Femtech Insider

Published: Jan. 20, 2025, 10:56 a.m.
A cRGD-modified liposome for targeted delivery of artesunate to inhibit angiogenesis in endometriosis.

Currently, hormonal therapy for endometriosis faces challenges in achieving a balance between treatment and preserving the chance of pregnancy. Therefore, the development of non-hormonal therapy holds significant clinical importance. Angiogenesis …

Published: Jan. 20, 2025, midnight
Single-cell and spatial transcriptomic profiling revealed niche interactions sustaining growth of endometriotic lesions.

Endometriosis is a chronic condition with limited therapeutic options. The molecular aberrations promoting ectopic attachment and interactions with the local microenvironment sustaining lesion growth have been unclear, prohibiting development of …

Published: Jan. 11, 2025, midnight
M2 Macrophages are Major Mediators of Germline Risk of Endometriosis and Explain Pleiotropy with Comorbid Traits.

Endometriosis is a common gynecologic condition that causes chronic life-altering symptoms including pain, infertility, and elevated cancer risk. There is an urgent need for new non-hormonal targeted therapeutics to treat …

Published: Nov. 22, 2024, midnight
[Exploring non-hormonal therapies and drug repositioning for endometriosis: insights from mouse model studies].

The mainstay of treatment for endometriosis is hormonal therapy, which suppresses ovulation; therefore, patients cannot conceive during treatment. There is a dilemma with ovarian-sparing surgery, known as laparoscopic cystectomy, as …

Published: Nov. 6, 2024, midnight
Non-Hormonal Therapy for Endometriosis Based on Angiogenesis, Oxidative Stress and Inflammation.

Endometriosis is a common gynecological disease that occurs in between 6 and 10% of women who are at reproductive maturity. The presence of endometrial tissue outside the uterine cavity is …

Published: Oct. 30, 2024, midnight
The long road of drug development for endometriosis - Pains, gains, and hopes.

Endometriosis, defined by the growth of endometrial tissues outside of the uterine cavity, is a global health burden for ~200 million women. Patients with endometriosis usually present with chronic pain …

Published: Oct. 18, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!